Today: 1 July 2026
Browse Category

NASDAQ:SGEN 9 January 2026 - 24 June 2026

Pfizer (NYSE:PFE) churns as investors price in bigger cancer pipeline discount after Seagen drug miss

Pfizer (NYSE:PFE) churns as investors price in bigger cancer pipeline discount after Seagen drug miss

Pfizer traded near flat in early premarket hours on Wednesday after a round of heavy selling that didn’t move the price much. Shares were at $24.76 at 7:07 a.m. EDT, just 0.16% higher than Tuesday’s $24.72 close. The stock is down about 14% from its 52-week high and up around 7% from its low. Pfizer shares ended down 1.44% on Tuesday. Volume was huge, with 81.9 million shares traded—well above the 50-day average of 36.8 million. Notional turnover at the close was about $2.0 billion, a lot for just one day tied to a clinical update. The S&P 500 dropped 1.44% too, but Pfizer trailed rival drugmakers: Johnson & Johnson gained 3.37%, Eli Lilly added 0.45%.
24 June 2026
·
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

New York, January 9, 2026, 12:09 EST — Regular session Merck & Co Inc shares were up about 0.4% at $111.41 on Friday as investors weighed a report that the drugmaker is in talks to buy cancer biotech Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped nearly 16% in extended trading on Thursday after the Financial Times report, which said talks were not final and could still take weeks, with other large drugmakers still circling; Merck and Revolution did not respond to requests for comment. The potential acquisition would be the biggest in the sector since Pfizer’s $43 billion Seagen deal and would add Revolution’s late-stage RAS cancer drug candidate daraxonrasib; Mizuho analysts estimate Revolution’s RAS inhibitors could generate more than $10 billion in risk-adjusted sales by 2035 as Merck looks past Keytruda patent expiries later this decade.
9 January 2026
···

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Go toTop